您好,欢迎访问浙江省农业科学院 机构知识库!

Engineering probiotic Escherichia coli Nissle 1917 to block transfer of multiple antibiotic resistance genes by exploiting a type I CRISPR-Cas system

文献类型: 外文期刊

作者: Fang, Mengdie 1 ; Zhang, Ruiting 1 ; Wang, Chenyu 1 ; Liu, Zhizhi 1 ; Fei, Mingyue 1 ; Tang, Biao 3 ; Yang, Hua 3 ; Sun, Dongchang 1 ;

作者机构: 1.Zhejiang Univ Technol, Coll Biotechnol & Bioengn, Hangzhou, Zhejiang, Peoples R China

2.Hangzhou Med Coll, Sch Lab Med & Bioengn, Hangzhou, Zhejiang, Peoples R China

3.Zhejiang Acad Agr Sci, Inst Agroprod Safety & Nutr, State Key Lab Managing Biot & Chem Threats Qual &, Hangzhou, Zhejiang, Peoples R China

4.Univ Chinese Acad Sci, Key Lab Syst Hlth Sci Zhejiang Prov, Sch Life Sci, Hangzhou Inst Adv Study, Hangzhou, Zhejiang, Peoples R China

关键词: antibiotic resistance gene; probiotics;


Escherichia coli Nissle 1917; conjugation; CRISPR-Cas

期刊名称:APPLIED AND ENVIRONMENTAL MICROBIOLOGY ( 影响因子:3.7; 五年影响因子:4.5 )

ISSN: 0099-2240

年卷期: 2024 年 90 卷 10 期

页码:

收录情况: SCI

摘要: Many multidrug-resistant (MDR) bacteria have evolved through the accumulation of antibiotic resistance genes (ARGs). Although the potential risk of probiotics as reservoirs of ARGs has been recognized, strategies for blocking the transfer of ARGs while using probiotics have rarely been explored. The probiotic Escherichia coli Nissle 1917 (EcN) has long been used for treating intestinal diseases. Here, we demonstrate frequent transfer of ARGs into EcN both in vitro and in vivo, raising concerns about its potential risk of accumulating antibiotic resistance. Given that no CRISPR-Cas system was found in natural EcN, we integrated the type I-E CRISPR-Cas3 system derived from E. coli BW25113 into EcN. The engineered EcN was able to efficiently cleave multiple ARGs [i.e., mcr-1, bla(NDM-1), and tet(X)] encoding enzymes for degrading last-resort antibiotics. Through co-incubation of EcN expressing Cas3-Cascade and that expressing Cas9, we showed that the growth of the former strain outcompeted the latter strain, demonstrating a better clinical application prospect of EcN expressing the type I-E CRISPR-Cas3 system. In the intestine of a model animal (i.e., zebrafish), the engineered EcN exhibited immunity against the transfer of CRISPR-targeted ARGs. Our work equips EcN with immunity against the transfer of multiple ARGs by exploiting the exogenous type I-E CRISPR-Cas3 system, thereby reducing the risk of the spread of ARGs while using it as a probiotic chassis for generating living therapeutics.

  • 相关文献
作者其他论文 更多>>